Incyte Highlights New Tafasitamab Data in Follicular Lymphoma at ASH 2024
Key Insights
Incyte will present new data from its oncology portfolio at the 2024 American Society of Hematology (ASH) Annual Meeting in San Diego.
A late-breaking oral presentation will feature results from the Phase 3 inMIND study evaluating tafasitamab in relapsed or refractory follicular lymphoma (search) (FL).
Incyte will host a virtual analyst and investor event on December 12, 2024, to discuss key data presentations from ASH.
Incyte (INCY) is set to present new data from its oncology portfolio at the 2024 American Society of Hematology (ASH) Annual Meeting in San Diego. The presentations will highlight advances across seven of the company's medicines.
Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte, stated, "These data illustrate our innovative approach that aims to identify new and best-in-class treatments for patients with a range of cancers. At ASH, we're presenting comprehensive data from our Phase 3 inMIND trial in relapsed or refractory follicular lymphoma (search). This late-breaking presentation provides valuable insights into the potential role of tafasitamab in improving outcomes for FL patients who currently face limited effective treatment options."
Tafasitamab Data in Follicular Lymphoma
A late-breaking oral presentation will feature results from the Phase 3 inMIND study, evaluating tafasitamab in combination with lenalidomide and rituximab for relapsed or refractory follicular lymphoma (search). The session, titled "Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase 3 Study (inMIND)," is scheduled for December 10 at 10:30 a.m. ET.
Additional Presentations
In addition to the tafasitamab presentation, Incyte will feature several other oral and poster presentations, including:
- Axatilimab: Dynamics of Overall and Organ-Specific Responses to Axatilimab in Chronic Graft-Versus-Host Disease: Analysis from the AGAVE-201 Study
- INCB057643: Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitor INCB057643 in Patients with Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 Study
- Ruxolitinib (Myeloproliferative Neoplasms [MPN]): Clinical and Molecular Characterization of Disease Progression in Patients (Pts) with Low-Risk Myelofibrosis (MF) Enrolled in the MOST Study
- Ruxolitinib (Graft-versus-host Disease [GVHD]): Real-World Ruxolitinib and Corticosteroid Treatment Patterns in Patients with Chronic Graft-Versus-Host Disease in the United States
- Ponatinib: The Impact of Ponatinib on Pregnancy Outcomes
Conference Call and Webcast
Incyte will host a conference call and webcast on Thursday, December 12, 2024, from 4:00-5:00 p.m. ET, to discuss key data presentations at ASH, including data from the Phase 3 inMIND study and its BET inhibitor program. The live webcast with slides can be accessed at Investor.Incyte.com and will be available for replay for ninety days.